TickerGuard
Buy Day today: Neutral (46) Mixed market breadth · no major macro event
VTGN

VistaGen Therapeutics Inc

Healthcare · Biotechnology

0.1683$ -1.4% vs. previous close Closing price · As of: Oct 30, 2026

Ownership

Ownership Structure

Who owns VistaGen Therapeutics Inc (VTGN)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 93.3% of the shares are freely tradable; institutional investors hold 40.8%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 40.8%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 0.2%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 93.3%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 8.5%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 44Mio.

Largest Shareholders

Institutions

Institutions VTGN
Name Stake (%) Shares Change (%) Date
COMMODORE CAPITAL LP 6.28 2,788,620 +0.0 06/30/2026
Vanguard Capital Management, LLC 3.55 1,574,200 +0.0 06/30/2026
Two Sigma Investments LLC 1.91 847,992 +80.6 06/30/2026
Acadian Asset Management LLC 1.79 794,579 +34.8 06/30/2026
Renaissance Technologies Corp 1.65 730,500 +150.8 06/30/2026
StemPoint Capital LP 1.39 616,749 -50.0 06/30/2026
Ikarian Capital, LLC 1.17 519,077 +0.0 06/30/2026
AdvisorShares Investments, LLC 0.99 438,643 +58.3 06/30/2026

Funds

Funds VTGN
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 2.62 1,160,455 +0.0 09/30/2026
AdvisorShares Psychedelics ETF 1.22 542,684 +0.0 09/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?